1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 136.63 | 95.83 | 68.65 |
| Total Income | 192.87 | 138.44 | 82.66 |
| Profit After Tax | 5.03 | 10.46 | 20.00 |
| EBITDA | 31.44 | 17.12 | 9.51 |
| NET Worth | 58.97 | 38.90 | 28.34 |
| Total Borrowing | 26.07 | 15.49 | 11.24 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Funding capital expenditure requirements for setting up a new project to enhance existing manufacturing capacities and manufacture new products; and | 226.25 |
| 2 | General Corporate Purposes |
About Cotec Healthcare IPO
Incorporated in 1998, Cotec Healthcare Limited operates as a Contract Development and Manufacturing Organization (CDMO) with capabilities across 24 distinct formulation types. The company manufactures a wide range of products including injectables, tablets, capsules, ointments, eye drops, ampoules, vials, liquid and dry syrups, and infusions. Its portfolio covers multiple therapeutic areas such as anaesthetics, analgesic/anti-inflammatory, antibiotics, anti-asthmatics, cardiovascular, dermatology, endocrinology and women’s health, clinical nutrition, vitamins, multivitamins, multimineral & supplements, and others. The company’s manufacturing facility is located in Roorkee, Uttarakhand, covering 21,871.71 square meters, with an installed capacity of 4,051.38 million units as of March 31, 2025. Cotec Healthcare Limited served 154, 177, and 122 customers during Fiscal 2025, 2024, and 2023, respectively. Key CDMO customers include Mankind Pharma Limited, German Remedies Pharmaceuticals Private Limited, Albert David Limited, Bion Therapeutics India Private Limited, Jagsonpal Pharmaceuticals Limited, and Makers Laboratories Limited. The company’s operations span both domestic and interna
Contact Details
Cotec Healthcare Ltd. AddressKishanpur, Bhagwanpur, NH-74Roorkee Dehradun HighwayBhagwanpur Haridwar,Roorkee, Uttarakhand, 247661+91 133 223 2248secretarial@cotec.inVisit Website